DIP Ep 675: USMLE Pharm Crash Course, The Drugs That Matter (Part 6, Final)

» Divine Intervention Podcasts

This episode concludes a six-part USMLE pharmacology crash course series, focusing on high-yield critical antibiotics frequently tested on medical board exams. Host Divine systematically breaks down the

Key takeaways

• Aminoglycosides (gentamicin, tobramycin, amikacin) are bactericidal 30S inhibitors that cause dose-dependent nephrotoxicity and irreversible ototoxicity, with risks amplified when combined with loop diuretics or vancomycin.
• Vancomycin's Redman syndrome is a direct mast cell degranulation reaction triggered by rapid infusion speed rather than an IgE-mediated allergy, managed by slowing the drip instead of stopping the drug.

Main topics

• Aminoglycoside pharmacology and toxicity
• Vancomycin infusion reactions and mechanisms

Notable quotes

"It's not an allergy, right? One common misconception many people have... is people thinking that, ooh, this is some kind of allergy. No, it's not."

Conclusion

The episode provides a highly targeted, exam-focused review of antibiotic pharmacology

Transcript preview

Speaker 1 (0:00) All right, welcome everyone. My name is Divine. This is episode 675 of the Divine Intervention podcasts. And here today, we're going to be finishing up the series on the farm crash course, you know, the drugs that matter. It's been a six part series, super high yield series, started in episode 670. So make sure you kind of check it out. So let's jump right in. So, you know. And today we're going to focus on a lot of the very critical antibiotics. I've kind of talked about some already, but I think it'll be helpful to kind of focus on some very critical ones. Like you don't want to walk into any USMLE exam not knowing about these ones, right? So what if they give you a question about a patient and they tell you that this patient has a history of a heart failure, right? And, you know, has been on pharmacotherapy, you know, been on combination pharmacotherapy for a while, but that this person was recently diagnosed with a lung infection. and the patient was placed on an antibiotic. And now this person has, you know, like two or three weeks after, you know, treatment, the person has had to be, you know, cranking up the TV to hear anything at home and things like that. So what antibiotic drug class was most likely used to treat the person's infection. So I really hope you're saying that this person probably used an aminoglycoside, right? An aminoglycoside, right? So... And we're going to see how this links with his heart failure presentation and things of that nature, right? So remember your aminoglycosides, the representative ones you may see on your exams are going to be things like gentamicin, tobramycin, amikacin, you know, amikacin is spelled A-M-A-M-I-K-A-C-I-N, right? So how do these drugs work? They basically bind the 30S ribosomal subunit, right? And when they bind it, so their 30S inhibitors, they basically cause misreading of the mRNA, right? So you essentially don't make... functional proteins. So because you don't make functional proteins, it basically destroys the bacteria, right? They are bactericidal, right? That's actually pretty unusual for most protein synthesis inhibitors. Most protein synthesis inhibitors are bacteriostatic, right? So this one is bactericidal. So that's kind of important. And the two big effects you want to know, and then I'm going to circle back to what I talked about earlier on, is that again, number one, they are nephrotoxic, right? Because they love to accumulate within the cells of the proximal tubule. Right. Remember, the proximal tubule is like the workhorse of the nephron. Does a lot of reabsorption, does a lot of active transport and things like that. Right. Again, our friends at the NBMEs know that all of you have memorized that. Ooh, this stuff is nephrotoxic. But again, this point about accumulation within the proximal tubule is not a point that many resources make. And it's not a point that many people understand. So that's something you certainly want to make sure you know for your exams. Definitely want to make sure you know for your exams. And then you also want to make sure you know that these drugs are autotoxic, right? So it can affect either hearing or it can affect vestibular function or it can affect both, right? And when it happens, it's usually irreversible, usually irreversible, right? And again... Prognosis, prognosis, prognosis. The USMLEs, if there is a prognostic angle with something, they love to take those angles these days, right? So, for example, like they can say, oh, which of the following elements in the patient's care most increase this risk of developing this adverse effect, right? Is again, dose, right? The higher the dose, the higher the risk of this nephron or ototoxicity, right? And duration of therapy, right? Those are two things you want to make sure you know in your exams, the two Ds. dose and duration of therapy right so you're developing these adverse effects is dependent on how much you get and how long you're on the drug for right so that's why if you notice in the hospital they monitor like the peak and trial levels of this this these drugs right they get very monitored very closely right because again that that's kind of like the having her to problems, right? And again, you want to make sure that you know drug interactions. That's the thing, the USMLEs with pharmacology these days, the unusual ways they go after things are drug interactions, prognosis, things of that nature, right? So you want to be careful with that. Hey, you don't want to combine an aminoglycoside with a loop diuretic if you can avoid it, or an aminoglycoside with vancomycin if you can avoid it, right? Because again, that'll pretty much juice up your nephrotoxic and ototoxic risk. Right. So like, for example, this person has a history of heart failure. Most people that have heart failure, they're on water pills, right? They're on loop diuretics to help with pulmonary edema. Well, go figure. That can cause problems, right? Because you're basically combining two nephrotoxic and ototoxic medications together. So that's something you just want to be careful about on your exams. So that's number one. Number two. is also don't forget that amino glycosides, right, they're neuromuscular blocking agents, right? So it's not a good idea. If a person has a history of like a neuromuscular disorder, like myasthenia gravis, an amino glycoside may not be the smartest decision there. All right. And then the next one I'm going to talk about, right, so let's talk about vancomycin, right? It's also nephron autotoxic since we're talking about those. Let's kind of lump those together, right? But remember vancomycin, how does it work? It's a cell wall inhibitor, right? Venk is a cell wall inhibitor, right? So it basically binds the D-ALA, D-ALA, you know, terminal of peptidoglycan, right? And then when it does that, it pretty much... blocks transpeptidation, right? Transpeptidation, you're pretty much disrupting the formation of that bond that holds the cell wall together, right? Now, the big, big, big side effect, right? Many of you probably know is Redman syndrome, right? It's like a vancomycin infusion reaction. But the thing is, you want to be a little more precise. Again, I can pretty much almost promise you, the USMLEs are not going to give you a venk question and put Redman syndrome as the answer. That's insane. No, they're not going to do that. Now, What they're going to do is they're going to ask the mechanism, right? They're going to ask the mechanism. There are certain nooks, again, like these pool changes they've done in recent months. Honestly, it's just about getting a little more granular with some of these things that they test. So let's get a little granular with the Redman syndrome, right? So remember, it's not an allergy, right? One common misconception many people have, and the USMLEs, they love to test, is people thinking that, ooh, this is some kind of allergy. No, it's not. It's